A phase II, randomized, partially double blind, controlled study to evaluate the immunogenicity, safety, and clinical efficacy of three doses of Neovacs� TNF-Kinoid in adult patients with rheumatoid arthritis (RA) who have relapsed despite use of an anti-

The primary objective of this study is to identify the best dose and schedule of administration of TNF-K in terms of anti-TNF? antibody response induced by two or three injections of TNF-K (Day 0, 28 or Day 0, 7, 28) at three dose levels (90, 180 or 360 mcg).